KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

GoodRx Holdings (GDRX) Debt to Equity (2019 - 2025)

GoodRx Holdings' Debt to Equity history spans 7 years, with the latest figure at $0.79 for Q4 2025.

  • For Q4 2025, Debt to Equity rose 16.76% year-over-year to $0.79; the TTM value through Dec 2025 reached $0.79, up 16.76%, while the annual FY2025 figure was $0.79, 16.76% up from the prior year.
  • Debt to Equity for Q4 2025 was $0.79 at GoodRx Holdings, down from $0.81 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.04 in Q1 2024 and bottomed at $0.68 in Q4 2024.
  • The 5-year median for Debt to Equity is $0.8 (2021), against an average of $0.81.
  • The largest annual shift saw Debt to Equity skyrocketed 32.92% in 2024 before it decreased 27.59% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.8 in 2021, then grew by 1.44% to $0.81 in 2022, then grew by 6.56% to $0.86 in 2023, then dropped by 21.24% to $0.68 in 2024, then grew by 16.76% to $0.79 in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Debt to Equity are $0.79 (Q4 2025), $0.81 (Q3 2025), and $0.76 (Q2 2025).